Pneumococcal vaccination of older adults: conjugate or polysaccharide?

@article{Fedson2013PneumococcalVO,
  title={Pneumococcal vaccination of older adults: conjugate or polysaccharide?},
  author={David S. Fedson and Martin J Guppy},
  journal={Human vaccines & immunotherapeutics},
  year={2013},
  volume={9 6},
  pages={1382-4}
}
Invasive pneumococcal disease continues to be important problem for older adults. Pneumococcal polysaccharide vaccine (PPV23) has a clinical effectiveness of 43-81%, and following primary vaccination and revaccination, antibody responses last 5-10 y. Hyporesponsiveness to a second dose of vaccine has not been shown to be a significant problem. The use of pneumococcal conjugate vaccines (initially PCV7; more recently PCV13) has led to a dramatic fall in the incidence of conjugate vaccine-type… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…